ATAI - ATA Inc-China Stock Price, Fair Value and News

1.72USD-0.14 (-7.53%)Delayed

Market Summary

USD1.72-0.14

Delayed

-7.53%

ATAI Stock Price

View Fullscreen

ATAI RSI Chart

ATAI Valuation

Market Cap

287.9M

Price/Earnings (Trailing)

-3.28

Price/Sales (Trailing)

917

EV/EBITDA

-9.34

Price/Free Cashflow

-3.37

ATAI Price/Sales (Trailing)

ATAI Profitability

EBT Margin

-10131.05%

Return on Equity

-39.42%

Return on Assets

-32.6%

Free Cashflow Yield

-29.71%

ATAI Fundamentals

ATAI Revenue

Revenue (TTM)

314.0K

Rev. Growth (Yr)

-52.63%

Rev. Growth (Qtr)

-79.31%

ATAI Earnings

Earnings (TTM)

-87.7M

Earnings Growth (Yr)

19.38%

Earnings Growth (Qtr)

63.01%

Breaking Down ATAI Revenue

Last 7 days

-9.0%

Last 30 days

-13.1%

Last 90 days

-6.5%

Trailing 12 Months

-7.5%

How does ATAI drawdown profile look like?

ATAI Financial Health

Current Ratio

7.83

Debt/Equity

0.07

Debt/Cashflow

-5.65

ATAI Investor Care

Shares Dilution (1Y)

0.84%

Diluted EPS (TTM)

-0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	252.0K	271.0K	334.0K	314.0K
2022	0	13.7M	6.9M	233.0K
2021	0	0	0	20.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ATA Inc-China

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	johnson anne nagengast	sold	-50,708	1.85	-27,410	chief financial officer
Apr 02, 2024	kirpekar sahil	sold	-66,231	1.85	-35,801	chief business officer
Apr 02, 2024	rao srinivas	sold	-114,034	1.85	-61,640	see remarks
Mar 14, 2024	johnson anne nagengast	acquired	-	-	100,000	chief financial officer
Mar 14, 2024	kirpekar sahil	acquired	-	-	100,000	chief business officer
Mar 14, 2024	rao srinivas	acquired	-	-	175,000	see remarks
Mar 14, 2024	brand florian	acquired	-	-	350,000	see remarks
Nov 16, 2023	brand florian	bought	23,120	1.156	20,000	see remarks
Sep 13, 2023	brand florian	bought	57,968	1.4492	40,000	see remarks
Mar 29, 2023	brand florian	bought	103,558	1.4794	70,000	see remarks

Which funds bought or sold ATAI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-77.71	-153,709	69,522	-%
May 15, 2024	MARSHALL WACE, LLP	added	2.31	469,859	1,563,860	-%
May 15, 2024	D. E. Shaw & Co., Inc.	sold off	-100	-152,517	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-27.76	5,606	606,417	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	96.44	274,638	432,056	-%
May 15, 2024	Royal Bank of Canada	added	3.13	30,000	102,000	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-3.55	203,742	789,940	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	191	3,293,880	4,366,540	-%
May 15, 2024	Cresset Asset Management, LLC	reduced	-96.3	-416,658	22,716	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	sold off	-100	-25,312	-	-%

Are Funds Buying or Selling ATAI?

Are funds buying ATAI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATAI

No. of Funds

Unveiling ATA Inc-China's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	apeiron investment group ltd.	20.1%	33,885,999	SC 13G/A
Feb 10, 2023	apeiron investment group ltd.	19.4%	32,671,702	SC 13G/A
Mar 01, 2022	galaxy group funding eci u llc	6.7%	10,796,736	SC 13G
Feb 10, 2022	apeiron investment group ltd.	19.7%	32,059,504	SC 13G

Recent SEC filings of ATA Inc-China

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 03, 2024	144	Notice of Insider Sale Intent
May 03, 2024	4	Insider Trading
May 03, 2024	SC 13D/A	13D - Major Acquisition
Apr 22, 2024	DEF 14A	DEF 14A
Apr 17, 2024	4	Insider Trading
Apr 12, 2024	PRE 14A	PRE 14A
Apr 08, 2024	144	Notice of Insider Sale Intent
Apr 05, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to ATA Inc-China)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

ATA Inc-China News

Latest updates

ATA Inc-China Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-100.0%	-	18,000	87,000	172,000	37,000	38,000	24,000	127,000	230,000	266,000	-	19,880,000
Operating Expenses	-28.3%	24,085,000	33,579,000	26,921,000	32,034,000	33,251,000	37,603,500	38,447,000	35,527,000	45,405,000	33,627,000	61,319,000	15,830,000
S&GA Expenses	-100.0%	-	19,423,000	13,631,000	16,558,000	13,970,000	15,727,500	19,419,000	17,221,000	25,877,000	20,264,000	37,331,000	9,273,000
EBITDA Margin	20.7%	-91.75	-115	-171	-497	-534	-575	-20.77	-10.08	-6.70	-	-	-
Interest Expenses	-8.9%	629,000	690,500	686,000	658,000	622,000	923,000	-	-	-	-	-	-
Income Taxes	-100.9%	-4,000	423,500	200,000	185,000	200,000	6,033,000	100,000	51,000	3,557,000	400,000	58,000	6,000
Earnings Before Taxes	-40.2%	-25,681,000	-18,319,500	43,847,000	-31,658,000	-33,156,000	-39,321,000	-33,134,000	-30,806,000	-48,579,000	-26,474,000	-67,301,000	5,753,000
EBT Margin	19.0%	-101	-125	-180	-506	-541	-580	-20.79	-10.09	-6.70	-	-	-
Net Income	63.0%	-26,713,000	-72,223,500	44,244,000	-33,042,000	-33,135,000	-45,011,000	-33,887,000	-36,618,000	-88,877,000	-31,158,000	-48,461,000	688,000
Net Income Margin	6.8%	-279	-299	-200	-535	-589	-654	-28.25	-14.17	-8.24	-	-	-
Free Cashflow	-2.7%	-22,573,000	-21,970,000	-18,431,000	-22,585,000	-21,391,000	-30,647,000	-28,504,000	-22,047,000	-20,561,000	-27,933,000	1,774,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-8.3%	269	293	308	254	281	305	343	349	384	414	484	506	112
Current Assets	-36.7%	118	186	216	243	268	287	317	324	349	375	442	458	100
Cash Equivalents	-24.7%	34.00	45.00	76.00	141	186	191	143	84.00	124	362	430	454	97.00
Net PPE	-6.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-6.7%	46.00	49.00	40.00	38.00	40.00	40.00	47.00	29.00	29.00	28.00	21.00	21.00	16.00
Current Liabilities	-25.4%	15.00	20.00	20.00	18.00	20.00	20.00	26.00	22.00	22.00	21.00	15.00	14.00	12.00
Short Term Borrowings	-20.0%	87.00	109	-	-	-	-	-	-	-	-	0.00	0.00	-
Long Term Debt	0.6%	15.00	15.00	15.00	15.00	15.00	15.00	15.00	-	-	-	-	-	-
Shareholder's Equity	-8.4%	223	243	266	213	237	261	289	312	346	377	453	475	91.00
Retained Earnings	-4.9%	-577	-550	-532	-576	-543	-510	-465	-431	-394	-357	-268	-237	-189
Additional Paid-In Capital	0.7%	801	795	799	792	783	774	762	746	735	725	709	691	262
Shares Outstanding	0.1%	166	166	166	166	166	166	155	154	154	161	134	132	-
Minority Interest	-47.3%	1.00	1.00	2.00	3.00	4.00	5.00	7.00	8.00	8.00	9.00	10.00	10.00	5.00
Float	-	-	-	-	203	-	-	-	411	-	-	-	2,050	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-2.8%	-22,573	-21,962	-18,431	-22,614	-21,111	-30,505	-28,045	-21,931	-23,986	-20,509	-28,110	1,897	-16,524	-	-	-
Share Based Compensation	-21.1%	5,760	7,305	8,253	8,762	8,662	12,140	10,515	9,512	10,208	13,398	12,240	37,512	212	-	-	-
Cashflow From Investing	1493.8%	11,471	-823	-46,485	-22,005	16,018	80,052	66,050	-18,214	-214,736	-48,633	-614	-28,308	-3,721	-	-	-
Cashflow From Financing	100.0%	-	-8,461	-	-100	206	-922	19,781	1,794	132	1,723	3,877	373,763	30,499	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATAI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
License revenue	$ 0	$ 37
Operating expenses:
Research and development	11,530	19,281
General and administrative	12,555	13,970
Total operating expenses	24,085	33,251
Loss from operations	(24,085)	(33,214)
Other income (expense), net:
Interest income	307	275
Interest expense	(687)	(622)
Benefit from research and development tax credit	205	0
Change in fair value of assets and liabilities, net	(1,200)	999
Foreign exchange loss, net	(216)	(837)
Other income (expense), net	(5)	243
Total other income (expense), net	(1,596)	58
Loss before income taxes	(25,681)	(33,156)
Benefit from (provision for) income taxes	4	(165)
Losses from investments in equity method investees, net of tax	(1,701)	(1,033)
Net loss	(27,378)	(34,354)
Net loss attributable to noncontrolling interests	(665)	(1,219)
Net income (loss) attributable to ATAI Life Sciences N.V. stockholders	$ (26,713)	$ (33,135)
Net income (loss) per share attributable to ATAI Life Sciences N.V. shareholders - basic	$ (0.17)	$ (0.21)
Net income (loss) per share attributable to ATAI Life Sciences N.V. stockholders - diluted	$ (0.17)	$ (0.21)
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V.Stockholders - basic	158,891,067	155,792,490
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - diluted	158,891,067	155,792,490

ATAI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 18,867	$ 45,034
Securities carried at fair value	87,379	109,223
Short term restricted cash for other investments	5,000	0
Committed Investment Funds	0	25,000
Prepaid expenses and other current assets	5,732	5,830
Short term notes receivable - related party, net	522	505
Total current assets	117,500	185,592
Long term restricted cash for other investments	10,000	0
Property and equipment, net	920	981
Operating lease right-of-use asset, net	1,115	1,223
Other Investments held at fair value	90,205	89,825
Other investments	32,807	1,838
Long term notes receivable - related parties, net	98	97
Convertible notes receivable - related party	13,902	11,202
Other assets	2,574	2,720
Total assets	269,121	293,478
Current liabilities:
Accounts payable	3,843	4,589
Accrued liabilities	10,926	15,256
Current portion of lease liability	244	275
Total current liabilities	15,013	20,120
Contingent consideration liability - related parties	607	620
Contingent consideration liability	1,406	1,637
Noncurrent portion of lease liability	907	990
Convertible promissory notes - related parties	159	164
Convertible promissory notes and derivative liability	4,357	2,666
Long-term debt, net	15,140	15,047
Other liabilities	8,275	7,918
Total liabilities	45,864	49,162
Commitments and contingencies (Note 16)
Stockholders' equity:
Common stock, 0.10 par value ($0.11 and $0.12 par value at March 31, 2024 and December 31, 2023, respectively); 750,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 166,274,426 and 166,026,396 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	18,600	18,573
Additional paid-in capital	800,520	794,787
Accumulated other comprehensive loss	(18,925)	(19,460)
Accumulated deficit	(577,651)	(550,938)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders	222,544	242,962
Noncontrolling interests	713	1,354
Total stockholders' equity	223,257	244,316
Total liabilities and stockholders' equity	$ 269,121	$ 293,478

About ATA Inc-China

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

CEO	Mr. Florian Brand
WEBSITE	atai.life
INDUSTRY	Biotechnology
EMPLOYEES	133

ATA Inc-China Frequently Asked Questions

What is the ticker symbol for ATA Inc-China? What does ATAI stand for in stocks?

ATAI is the stock ticker symbol of ATA Inc-China. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ATA Inc-China (ATAI)?

As of Fri May 17 2024, market cap of ATA Inc-China is 287.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATAI stock?

You can check ATAI's fair value in chart for subscribers.

What is the fair value of ATAI stock?

You can check ATAI's fair value in chart for subscribers. The fair value of ATA Inc-China is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ATA Inc-China is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATAI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ATA Inc-China a good stock to buy?

The fair value guage provides a quick view whether ATAI is over valued or under valued. Whether ATA Inc-China is cheap or expensive depends on the assumptions which impact ATA Inc-China's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATAI.

What is ATA Inc-China's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ATAI's PE ratio (Price to Earnings) is -3.28 and Price to Sales (PS) ratio is 917. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATAI PE ratio will change depending on the future growth rate expectations of investors.